Related Experiment Video

Updated: Aug 29, 2026

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

Harnessing apoptosis for improved anticancer gene therapy

David J Waxman1, Pamela S Schwartz

  • 1Division of Cell and Molecular Biology, Department of Biology, Boston University, Boston, Massachusetts 02215, USA. djw@bu.edu

Cancer Research
|December 26, 2003
PubMed

Insights

Novel cancer therapies combine gene therapy with drug treatments to enhance tumor cell death. This strategy uses anti-apoptotic factors to prolong drug effectiveness and improve cancer treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Understanding tumor cell responses to DNA damage is crucial for developing targeted cancer therapies.
  • Proapoptotic factors can sensitize cancer cells to chemotherapy, but antiapoptotic factors are often linked to poor prognosis.
  • Novel strategies explore combining antiapoptotic factors with gene therapy to overcome treatment resistance.

Purpose of the Study:

  • To investigate the potential of combining antiapoptotic factors with gene-directed enzyme prodrug therapy for cancer treatment.
  • To explore how antiapoptotic factors can be used to enhance the efficacy of traditional chemotherapeutic drugs.
  • To adapt this model for other gene therapies targeting cell death pathways.

Main Methods:

  • Utilizing the baculovirus protein p35 (an antiapoptotic, caspase-inhibitory factor) in combination with P-450 gene-directed enzyme prodrug therapy.
  • Administering cyclophosphamide as a prodrug activated by P-450.
  • Focusing on localized, intratumoral drug metabolite production.

Main Results:

  • The combination therapy prolonged localized production of cytotoxic drug metabolites.
  • This approach did not induce tumor cell drug resistance.
  • The antiapoptotic factor acted downstream of mitochondrial transition delays, allowing for ultimate cell death.

Conclusions:

  • Combining antiapoptotic factors with gene-directed enzyme prodrug therapy offers a promising strategy to enhance cancer treatment.
  • This model can be adapted for other gene therapies, including those targeting death receptor pathways.
  • Amplifying the therapeutic response by maximizing cytotoxic factors and prodrug metabolites is achievable.

More Related Videos

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size reduction of the tissue.
Gene Therapy01:22

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...